News & insights
Occasional writing on the practical side of pharmaceutical availability — the parts that determine whether a medicine reaches a patient, which rarely make the headline.
A first public description of the group’s integrated model across active ingredients, finished dosage manufacturing, global supply chain and clinical services — and of the staged approach that puts measured availability ahead of construction.
Further announcements, programme updates and written perspectives are in preparation and will be published here.
Next step
Most of what matters here is specific to a market and a portfolio. We are happy to discuss yours.